New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to speed up the process. https://t.co/Ey7gARsaCQ https://t.co/Ey7gARsaCQ ...

New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to speed up the process. https://t.co/mzlki2K93z https://t.co/mzlki2K93z ...

Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal DiseasesAugust 08, 2025 7:00 AM EDT | Source: Kiora Pharmaceuticals, Inc.Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced second quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key second ...

Catalyst Pharmaceuticals (CPRX) Q2 2025 Earnings Call August 07, 2025 08:30 AM ET Speaker0Greetings, and welcome to the Catalyst Pharmaceuticals Second Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to the Chief Financial Officer, Mike Kalb.Please go ahead, sir.Speaker1Thank you ...

Q2 2025 Earnings Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about our 2025 financial guidance; 2025 strategic priorities, including drive strong execution, advance our pipeline, prioritize capital return with focus on share repurchases, target accretive regional business d ...

Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates expected in 4Q25 Phase 2 trial of TERN-601 for obesity completed enrollment; 12-week efficacy, safety and tolerability data expected in early 4Q25 Cash runway into 2028 focused on advancing CML program internally and partnering metabolic assets Terns to host a TERN-701-focused educational webinar in September 2025 FOSTER CITY, Calif., Aug. 05, 2025 (GL ...

Industry Bottleneck - Clinical trial bottlenecks cause delays in new drugs reaching the market [1] AI Solution - AI-enabled technology is being developed to accelerate the clinical trial process [1] - Two cancer doctors are building the AI solution [1]

New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to speed up the process. https://t.co/SyqmEQnea7 https://t.co/SyqmEQnea7 ...

New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to speed up the process. https://t.co/YbATOyAUyO https://t.co/YbATOyAUyO ...

Industry Bottleneck - Clinical trial bottlenecks cause delays in new drug launches [1] - Two cancer doctors developed AI-enabled technology to accelerate the drug development process [1]